A263050 Share Price Performance
₩959.00
-311.00 (-24.49%)
Price ₩959.00
Share Pricen/a
Analysis Article • Nov 24
Eutilex.Co.,Ltd Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A263050 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Eutilex.Co.,Ltd Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -649.55
- 3.93%
- -232.38%
- 97.2%
About A263050
- Founded
- 2008
- Employees
- n/a
- CEO
- WebsiteView website
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headquartered in Seoul, South Korea.
